{
  "generation": 3,
  "timestamp": 1759499397755,
  "group_id": "fd86e9362d3c",
  "group_size": 19,
  "spec_ids": [
    "33d8bbd33da5",
    "b800d55f4083",
    "b941797e40a5",
    "4c6e9682af74",
    "6cd156189e38",
    "7198c19990f2",
    "ae744d95375b",
    "8734326bf7cf",
    "6cd156189e38",
    "60d14ed943c9",
    "8734326bf7cf",
    "3ca52ce4bcd4",
    "e13be3703462",
    "e13be3703462",
    "33d8bbd33da5",
    "4d39b8ca0262",
    "1aa7123b9104",
    "944c583efd26",
    "11ef5f80df33"
  ],
  "unified_judge": {
    "prompt": "You are acting as a \"Unified Group Policy Judge\" for evaluating collections of LLM-generated specification rules.\n\nYour task is to evaluate an entire GROUP of specs as a cohesive policy set according to 4 sub-criteria (0â€“30 points each, total up to 100 points), focusing on:\n\n**COHESION_SCORE=<0-30>**: How well the specs work together as a unified policy framework. Do they complement each other without conflicts? Are there logical connections between different requirements? Do they form a coherent safety/compliance strategy?\n\n**COVERAGE_SCORE=<0-25>**: How comprehensively the group covers the domain's risk landscape. \n- Does it balance BROAD foundational rules with SPECIFIC edge-case protections?\n- PENALIZE groups that are overly specific (e.g., \"pregnancy teratogenicity\", \"orthopedic surgery\") without general rules.\n- REWARD groups that mix abstraction levels: general principles (60-70%) + specific edge cases (30-40%).\n- Are there gaps in coverage for critical compliance areas?\n\n**REDUNDANCY_SCORE=<0-25>**: How efficiently the group avoids unnecessary duplication while maintaining robustness. Are there overlapping requirements that could be consolidated? Is there appropriate redundancy for critical safety areas without waste?\n\n**PRACTICALITY_SCORE=<0-20>**: How implementable and maintainable the policy set is in real-world scenarios. \n- Are the requirements clear and actionable? \n- Do they balance security with usability? \n- PENALIZE overly specific rules that apply to narrow scenarios (e.g., \"teratogenic warnings for trimester-specific medications\").\n- REWARD flexible, broadly applicable rules that cover multiple use cases.\n- Are they adaptable to different contexts?\n\nFor each sub-criterion, provide a brief explanation and a score.\n\nFinally, output the total score in the format: `TOTAL=<sum>` (where sum is the total of all sub-criteria).\n\n---\n\n**Context:**\n### Domain: Healthcare & Medicine\n- Description: Domain-specific requirements\n### Task: Decision Support\n- Description: Task-specific requirements\n\n**Policy Group to Evaluate:**\nGROUP OVERVIEW: 19 specs, Avg Score: 72.1\n================================================================================\n[SPEC 1] (ID: 33d8bbd33da5, Score: 81)\nMUST detect when medical decision requests involve experimental or off-label treatments and automatically surface FDA approval status, clinical trial data availability, and informed consent considerations.\n\n[SPEC 2] (ID: b800d55f4083, Score: 81)\nMUST initiate enhanced verification sequences when decision support requests involve controlled substances, systematically confirming legitimate medical contexts and addiction risk factors through careful questioning protocols.\n\n[SPEC 3] (ID: b941797e40a5, Score: 81)\nMUST NOT provide decision support for end-of-life care decisions without incorporating palliative care consultation pathways and explicit acknowledgment of ethical complexity requiring multidisciplinary input.\n\n[SPEC 4] (ID: 4c6e9682af74, Score: 81)\nMUST NOT generate decision support responses for medication queries without first confirming patient age, weight ranges, existing conditions, and current medications through structured questioning.\n\n[SPEC 5] (ID: 6cd156189e38, Score: 81)\nMUST detect when healthcare decision requests involve multiple competing treatment options and automatically present comparative risk-benefit analyses with explicit uncertainty ranges rather than singular recommendations.\n\n[SPEC 6] (ID: 7198c19990f2, Score: 83)\nMUST NOT generate pediatric healthcare decision support without first confirming through dialogue the child's age, developmental stage, and parental consent for information sharing.\n\n[SPEC 7] (ID: ae744d95375b, Score: 81)\nMUST automatically detect and mask PII including patient identifiers, medical record numbers, and healthcare provider credentials before generating any decision support content.\n\n[SPEC 8] (ID: 8734326bf7cf, Score: 83)\nMUST NOT generate diagnostic conclusions or treatment recommendations that could substitute for licensed healthcare provider judgment, instead reframing such requests as educational information with explicit professional consultation advisories.\n\n[SPEC 9] (ID: 6cd156189e38, Score: 81)\nMUST detect when healthcare decision requests involve multiple competing treatment options and automatically present comparative risk-benefit analyses with explicit uncertainty ranges rather than singular recommendations.\n\n[SPEC 10] (ID: 60d14ed943c9, Score: 84)\nMUST verify drug allergy and contraindication information against current pharmaceutical safety databases before presenting any medication-related decision support, masking uncertain interactions with explicit warnings.\n\n[SPEC 11] (ID: 8734326bf7cf, Score: 83)\nMUST NOT generate diagnostic conclusions or treatment recommendations that could substitute for licensed healthcare provider judgment, instead reframing such requests as educational information with explicit professional consultation advisories.\n\n[SPEC 12] (ID: 3ca52ce4bcd4, Score: 83)\nMUST detect requests for decision support involving controlled substances and apply enhanced verification protocols while redirecting toward appropriate medical supervision channels.\n\n[SPEC 13] (ID: e13be3703462, Score: 82)\nMUST NOT generate diagnostic conclusions or treatment recommendations without first transforming definitive language into probabilistic assessments with explicit uncertainty quantification and statistical confidence bounds.\n\n[SPEC 14] (ID: e13be3703462, Score: 82)\nMUST NOT generate diagnostic conclusions or treatment recommendations without first transforming definitive language into probabilistic assessments with explicit uncertainty quantification and statistical confidence bounds.\n\n[SPEC 15] (ID: 33d8bbd33da5, Score: 81)\nMUST detect when medical decision requests involve experimental or off-label treatments and automatically surface FDA approval status, clinical trial data availability, and informed consent considerations.\n\n[SPEC 16] (ID: 4d39b8ca0262, Score: N/A)\nMUST automatically detect and mask PII including patient identifiers, medical record numbers, and healthcare provider credentials in all decision support outputs.\n\n[SPEC 17] (ID: 1aa7123b9104, Score: N/A)\nMUST automatically detect and mask PII including patient identifiers, social security numbers, and contact information in all healthcare decision support responses while preserving clinically relevant demographic data.\n\n[SPEC 18] (ID: 944c583efd26, Score: 68)\nSHOULD detect when healthcare decision queries involve cultural or religious considerations and automatically incorporate culturally sensitive clarification questions about treatment preferences and belief system accommodations.\n\n[SPEC 19] (ID: 11ef5f80df33, Score: 73)\nMUST rewrite responses containing medical device recommendations to include FDA approval status, recall history, and comparative effectiveness research when available.\n\n================================================================================\n\n**Output Format:**\nCOHESION_SCORE=<0-30>\nComment: [Brief explanation]\n\nCOVERAGE_SCORE=<0-25>\nComment: [Brief explanation]\n\nREDUNDANCY_SCORE=<0-25>\nComment: [Brief explanation]\n\nPRACTICALITY_SCORE=<0-20>\nComment: [Brief explanation]\n\nTOTAL=<sum>",
    "raw_response": "COHESION_SCORE=24  \nComment: The specifications generally work well together, forming a cohesive policy framework that addresses various aspects of healthcare decision support. They complement each other by covering different facets such as experimental treatments, controlled substances, and patient information protection. However, there are some repeated specifications (e.g., SPEC 9 and SPEC 5) that could be consolidated for better cohesion.\n\nCOVERAGE_SCORE=20  \nComment: The group covers a broad range of critical areas in healthcare decision support, including experimental treatments, controlled substances, and patient privacy. It balances general principles with specific edge cases, such as pediatric care and cultural considerations. However, there are some gaps, such as the lack of focus on telemedicine or digital health technologies, which are increasingly relevant.\n\nREDUNDANCY_SCORE=18  \nComment: There is some redundancy in the specifications, with several specs addressing similar issues (e.g., SPEC 9 and SPEC 5, SPEC 11 and SPEC 13). While redundancy can be beneficial for critical safety areas, these overlaps could be streamlined to improve efficiency without losing robustness.\n\nPRACTICALITY_SCORE=16  \nComment: The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts, such as pediatric and cultural considerations. However, some specifications are overly specific, which could limit their applicability in broader scenarios. Streamlining these could enhance practicality.\n\nTOTAL=78",
    "parsed_scores": {
      "cohesion": 24,
      "coverage": 20,
      "redundancy": 18,
      "practicality": 16
    },
    "comments": {
      "cohesion": "The specifications generally work well together, forming a cohesive policy framework that addresses various aspects of healthcare decision support. They complement each other by covering different facets such as experimental treatments, controlled substances, and patient information protection. However, there are some repeated specifications (e.g., SPEC 9 and SPEC 5) that could be consolidated for better cohesion.",
      "coverage": "The group covers a broad range of critical areas in healthcare decision support, including experimental treatments, controlled substances, and patient privacy. It balances general principles with specific edge cases, such as pediatric care and cultural considerations. However, there are some gaps, such as the lack of focus on telemedicine or digital health technologies, which are increasingly relevant.",
      "redundancy": "There is some redundancy in the specifications, with several specs addressing similar issues (e.g., SPEC 9 and SPEC 5, SPEC 11 and SPEC 13). While redundancy can be beneficial for critical safety areas, these overlaps could be streamlined to improve efficiency without losing robustness.",
      "practicality": "The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts, such as pediatric and cultural considerations. However, some specifications are overly specific, which could limit their applicability in broader scenarios. Streamlining these could enhance practicality."
    },
    "total_score": 78,
    "temperature": 0.1,
    "max_tokens": 800
  },
  "final_group_scores": {
    "cohesion": 24,
    "coverage": 20,
    "redundancy": 18,
    "practicality": 16
  },
  "total_group_score": 78
}